p53 is a direct transcriptional target of MYCN in neuroblastoma.

MYCN amplification occurs in approximately 25% of neuroblastomas, where it is associated with rapid tumor progression and poor prognosis. MYCN plays a paradoxical role in driving cellular proliferation and inducing apoptosis. Based on observations of nuclear p53 accumulation in neuroblastoma, we hypothesized that MYCN may regulate p53 in this setting. Immunohistochemical analysis of 82 neuroblastoma tumors showed an association of high p53 expression with MYCN expression and amplification. In a panel of 5 MYCN-amplified and 5 nonamplified neuroblastoma cell lines, and also in the Tet21N-regulatable MYCN expression system, we further documented a correlation between the expression of MYCN and p53. In MYCN-amplified neuroblastoma cell lines, MYCN knockdown decreased p53 expression. In Tet21N MYCN+ cells, higher levels of p53 transcription, mRNA, and protein were observed relative to Tet21N MYCN- cells. In chromatin immunoprecipitation and reporter gene assays, MYCN bound directly to a Myc E-Box DNA binding motif located close to the transcriptional start site within the p53 promoter, where it could initiate transcription. E-Box mutation decreased MYCN-driven transcriptional activation. Microarray analysis of Tet21N MYCN+/- cells identified several p53-regulated genes that were upregulated in the presence of MYCN, including MDM2 and PUMA, the levels of which were reduced by MYCN knockdown. We concluded that MYCN transcriptionally upregulates p53 in neuroblastoma and uses p53 to mediate a key mechanism of apoptosis.

[1]  J. Lunec,et al.  The p53 pathway and its inactivation in neuroblastoma. , 2003, Cancer letters.

[2]  J. Lunec,et al.  Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. , 2001, Cancer research.

[3]  M. Schwab,et al.  MycN sensitizes neuroblastoma cells for drug-induced apoptosis , 1999, Oncogene.

[4]  A. Davidoff,et al.  Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. , 1992, Oncogene.

[5]  M. Schwab,et al.  MycN sensitizes neuroblastoma cells for drug-triggered apoptosis. , 2000, Medical and pediatric oncology.

[6]  Wafik S El-Deiry,et al.  p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. , 2006, Cancer research.

[7]  M. Hogarty.  The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. , 2003, Cancer letters.

[8]  S. Ferrari,et al.  Transcription of N-myc and proliferation-related genes is linked in human neuroblastoma. , 1991, Cancer letters.

[9]  D. Boger,et al.  Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. , 2008, Oncology reports.

[10]  M. Jackson,et al.  Histological profile of tumours from MYCN transgenic mice , 2008, Journal of Clinical Pathology.

[11]  K. Matthay,et al.  Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. , 2008, Neoplasia.

[12]  Rainer König,et al.  Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas , 2008, Genome Biology.

[13]  J. Charron,et al.  N-Myc shares cellular functions wiht c-Myc. , 2000, DNA and cell biology.

[14]  P. Farnham,et al.  Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. , 2002, Methods.

[15]  H. Hermeking,et al.  Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.

[16]  S. Ishii,et al.  Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. , 2005, Cancer cell.

[17]  Hiroyuki Shimada,et al.  Terminology and morphologic criteria of neuroblastic tumors , 1999, Cancer.

[18]  J. Armstrong,et al.  Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours , 2007, Apoptosis.

[19]  V. Rotter,et al.  c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[20]  W. Loging,et al.  Transcriptional regulation of the p53 tumor suppressor gene. , 1998, Seminars in cancer biology.

[21]  A. Pession,et al.  The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Stram,et al.  Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. , 1995, Journal of the National Cancer Institute.

[23]  U. Kees,et al.  Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. , 2006, Cancer research.

[24]  H. Ding,et al.  Linking of N-Myc to Death Receptor Machinery in Neuroblastoma Cells* , 2005, Journal of Biological Chemistry.

[25]  J. Lunec,et al.  Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene. , 2005, Gene.

[26]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[27]  D. Reisman,et al.  Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors , 1994, Molecular and cellular biology.

[28]  D. Stram,et al.  Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors , 2001, Cancer.

[29]  R. Pieters,et al.  The N-myc paradox: N-myc overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis. , 2003, Cancer letters.

[30]  Kathryn A. O’Donnell,et al.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets , 2003, Genome Biology.

[31]  M. Schwab,et al.  Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. , 1996, Oncogene.

[32]  N. Olgun,et al.  Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma. , 2007, Cancer genetics and cytogenetics.

[33]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[34]  U. Kees,et al.  The Role of MYCN in the Failure of MYCN Amplified Neuroblastoma Cell Lines to G1 Arrest After DNA Damage , 2006, Cell cycle.

[35]  R. Eisenman,et al.  Myc target genes. , 1997, Trends in biochemical sciences.

[36]  Holger Christiansen,et al.  Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. , 2002, Cancer cell.

[37]  D. Machin,et al.  High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. , 2008, The Lancet. Oncology.

[38]  F. Westermann,et al.  Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. , 2007, Cancer letters.

[39]  J. Lunec,et al.  p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. , 2001, The American journal of pathology.

[40]  M. Cole,et al.  p53 is Nuclear and Functional in Both Undifferentiated and Differentiated Neuroblastoma , 2007, Cell cycle.

[41]  M. Schwab,et al.  Suppression of centrosome amplification after DNA damage depends on p27 accumulation. , 2006, Cancer research.

[42]  K. Matthay,et al.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  O. Yanuka,et al.  Involvement of Myc targets in c-myc and N-myc induced human tumors , 1998, Oncogene.

[44]  S. Cohn,et al.  MYCN amplification remains prognostically strong 20 years after its "clinical debut". , 2004, European journal of cancer.

[45]  I. Bernstein,et al.  Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. , 2008, Cell stem cell.